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the Intended Use PopulationTo the Editor—Najafzadeh et al. [1] recently published in Value in
Health a cost-effectiveness analysis of a molecular diagnostic test
to improve preoperative diagnosis of thyroid cancer. The target
population for this analysis was patients with an initial indeter-
minate cytological diagnosis based on fine-needle aspiration
biopsy (FNAB). The path to surgical excision of suspected thyroid
cancer consists of a number of decisions, such as referral to an
endocrinologist, obtaining tissue for initial diagnosis via a FNAB,
referral to a surgical specialist, and ultimately surgical resection.
Wang et al. [2] recently assessed in a large, multicenter cohort
study (21 clinical sites, 753 prospectively collected FNABs) the
proportion of patients who underwent surgical resection. Among
the 61 patients with indeterminate pathology by FNAB, just 38
(62%) eventually underwent surgical resection, similar to the rate
(58%) found in their companion ‘‘meta-review’’ of the literature.
These rates are lower than expected based on guidelines from
the American Thoracic Association [3], with Wang et al. spec-
ulating that the low rates may be related to 1) loss to follow-up,
2) resection at a different institution than where the FNAB was
performed, and 3) comorbidities or preferences that preclude the
patient undergoing surgery. After adjusting for these factors,
they estimate that approximately 25% of the patients with
indeterminate pathology on FNAB do not undergo surgical
resection.
The sensitivity and specificity used in Najafzadeh et al.’s cost-
effectiveness analysis presumably are based on studies of
patients who have undergone surgical resection [4]. The test’s
accuracy therefore is known for the population of patients with
indeterminate pathology by FNAB who have undergone surgical
resection, but is not directly known for the population of patients
who do not undergo resection. What are the implications of these
data? Najafzadeh et al.’s cost-effectiveness analysis is valid when
clarifying the definition of the target population according to the
available evidence: Patients with an indeterminate cytological diag-
nosis based on fine-needle aspiration biopsy (FNABs) who have been
referred specifically for surgical resection. Given the existing evidence
and Najafzadeh et al.’s compelling analysis, it would be appro-
priate and cost-effective for a surgeon to order the test in patients
who have been referred, representing about 75% of the patients
with indeterminate pathology by FNAB, as an aid in the decision
on whether to proceed with surgical resection. The appropriate-
ness and cost-effectiveness of an endocrinologist ordering the
test to aid in the decision to refer to a surgeon, who presumably
could include all 100% patients with indeterminate pathology,ial support: The author has no other financial relhowever, is less certain. Wang et al. could identify no obvious
clinical characteristics that distinguished patients who did or did
not undergo surgical resection; hence, it may seem reasonable to
assume that the rate of thyroid cancer and the test character-
istics are similar in these two populations. But it is important
that clinicians and policymakers appreciate that this remains an
assumption.
Further research is needed to understand the appropriate use
and cost-effectiveness of the test at the referral decision point.
Long-term follow-up on the rate of thyroid cancer among the
patients who were not referred is needed. It would also be useful
to have direct evidence on the test’s accuracy in the population of
patients who traditionally are not destined to undergo surgical
resection. Enrolling such patients for the purpose of obtaining
tissues for a ‘‘gold-standard’’ pathological diagnosis carries ethi-
cal considerations, and may require sponsorship and oversight by
a nonpartial government research agency or nonprofit founda-
tion. This commentary highlights the relevance of modeling the
full sequence of decisions, who is making the decision, and how
knowledge of a novel test’s results alters decisions.
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